Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
RedactPHI
HIPAA-Compliant PHI Redaction
DetectICD10CM
ICD-10-CM Code Detection
Log in Register free account
1 code page views remaining. Guest accounts are limited to 1 page view. Register free account to get 5 more views.
Log in Register free account

Official Description

Influenza virus vaccine, H5N8, derived from cell cultures, adjuvanted, for intramuscular use

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 90695 refers to the influenza virus vaccine specifically targeting the H5N8 strain, which is derived from cell cultures and is adjuvanted for intramuscular use. The H5N8 influenza virus is recognized as a virulent strain of the avian influenza, commonly known as bird flu, which can be transmitted from animals to humans, primarily through contact with infected poultry or environments contaminated by poultry. This vaccine is produced using mammalian cell cultures, a method that eliminates the need for egg-based production, thereby reducing the risk of allergic reactions associated with egg proteins. The inclusion of adjuvants, such as squalene, DL-α-tocopherol, and polysorbate 80, enhances the immune response, leading to a more robust defense against the virus. It is important to note that this code specifically pertains to the vaccine product itself, and the administration of the vaccine via intramuscular injection is reported separately under a different code.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The H5N8 influenza virus vaccine is indicated for individuals who may be at risk of exposure to the H5N8 strain of the avian influenza virus. This includes, but is not limited to, individuals who work in environments with poultry or those who have close contact with birds. The vaccine is particularly important for healthcare professionals, poultry workers, and individuals living in areas where outbreaks of H5N8 have been reported.

  • Risk of Exposure Individuals who are in close contact with poultry or contaminated environments.
  • Occupational Health Healthcare workers and poultry industry employees who may encounter the virus.
  • Geographic Considerations Residents in regions experiencing outbreaks of H5N8.

2. Procedure

The administration of the H5N8 influenza virus vaccine involves several key procedural steps to ensure proper delivery and effectiveness of the vaccine. First, the healthcare provider must verify the patient's eligibility for the vaccine, taking into account any contraindications or previous allergic reactions to vaccines. Next, the provider prepares the vaccine by ensuring it is at the appropriate temperature and inspecting the vial for any abnormalities. Following this, the provider selects an appropriate site for intramuscular injection, typically the deltoid muscle of the upper arm. The injection site is then cleaned with an antiseptic to minimize the risk of infection. The vaccine is administered using a sterile syringe and needle, ensuring that the injection is delivered deep into the muscle tissue. After the injection, the provider may apply a bandage to the site and monitor the patient for any immediate adverse reactions. Finally, proper documentation of the vaccine administration, including the date, lot number, and site of injection, is recorded in the patient's medical record.

  • Step 1: Patient Verification Confirm the patient's eligibility and check for contraindications.
  • Step 2: Vaccine Preparation Ensure the vaccine is at the correct temperature and inspect the vial.
  • Step 3: Site Selection Choose the deltoid muscle for intramuscular injection.
  • Step 4: Site Cleaning Clean the injection site with an antiseptic.
  • Step 5: Vaccine Administration Administer the vaccine using a sterile syringe and needle.
  • Step 6: Post-Injection Care Apply a bandage and monitor the patient for reactions.
  • Step 7: Documentation Record the administration details in the patient's medical record.

3. Post-Procedure

After the administration of the H5N8 influenza virus vaccine, patients are typically monitored for a short period to observe for any immediate adverse reactions, such as allergic responses or injection site reactions. Common post-procedure care includes advising the patient to rest and hydrate adequately. Patients may experience mild side effects, such as soreness at the injection site, low-grade fever, or fatigue, which usually resolve within a few days. It is important for patients to be informed about these potential side effects and to seek medical attention if they experience severe or persistent symptoms. Additionally, patients should be advised to keep their vaccination records updated and to follow any recommended schedules for future vaccinations or boosters as indicated by public health guidelines.

Short Descr H5N8 VACC DRV CLL CUL ADJ IM
Medium Descr H5N8 VACCINE DRV CELL CUL ADJUVANTED FOR IM USE
Long Descr Influenza virus vaccine, H5N8, derived from cell cultures, adjuvanted, for intramuscular use
APC Status Indicator Non-Covered Service, not paid under OPPS
Type of Service (TOS) 1 - Medical Care
Berenson-Eggers TOS (BETOS) none
MUE Not applicable/unspecified.
Date
Action
Notes
2025-01-01 Added First appearance in codebook
2024-07-19 Added Code added. Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"